ZIA CP010218 10832 (ZIA) | |||
---|---|---|---|
Title | Cholecystectomy Risk Stratification (CRS) Study | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Koshiol, Jill | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $11,826 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Gallbladder (100.0%) | ||
Research Type | |||
Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors Technology and/or Marker Testing in a Clinical Setting |
|||
Abstract | |||
In Chile, gallbladder cancer is a leading cause of cancer death in women. Gallstones are the central risk factor for GBC and cause substantial inflammation in the gallbladder. Cholecystectomy can cure early stage (localized) tumors.1 Thus, early detection and treatment are critical to improve survival among patients with GBC. In Chile, which has among the highest rates of GBC worldwide, national policy dictates that individuals aged 35-49 with gallstones are prioritized for cholecystectomy, regardless of whether they have symptoms,2 leading to delayed treatment of older patients who are at higher GBC risk and likely overtreatment of patients who are at low risk. Although mortality from cholecystectomy is low (0-0.6%),3,4 surgery is not without risk. Complications of cholecystectomy, including bile duct injury, biliary leak, postoperative bleeding, and wound infection occur in 5% of patients, and bile duct damage occurs in approximately 1 out of every 200 patients.3 In addition, cholecystectomy has been associated with increased risk of gastrointestinal cancers,5 bringing into question the potential long-term consequences of preferentially cholecystectomizing young individuals, particularly those without symptoms from gallstones. Thus, there is an urgent need to triage the back-log of gallstone patients based on risk. Our objective is to measure inflammation markers in cholecystectomy patients and evaluate the ability of these markers to stratify patients with gallstones based on risk of prevalent GDC to triage the backlog of people on the cholecystectomy waiting list. We hypothesize that several markers, in particular IL-6, IL-16, CCL20, and sTNFR1, will be useful for risk stratification of individuals on the cholecystectomy waiting list who have GDC. We will also be able to use this resource to evaluate other risk factors for gallbladder dysplasia. |